2. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H,
et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012;22:1775–1789.
5. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009;136:629–641.
7. Khorshidi A, Dhaliwal P, Yang BB. Noncoding RNAs in tumor angiogenesis. Adv Exp Med Biol 2016;927:217–241.
8. Shen XH, Qi P, Du X. Long non-coding RNAs in cancer invasion and metastasis. Mod Pathol 2015;28:4–13.
10. Bar C, Chatterjee S, Thum T. Long noncoding RNAs in cardiovascular pathology, diagnosis, and therapy. Circulation 2016;134:1484–1499.
14. Wu GC, Pan HF, Leng RX, Wang DG, Li XP, Li XM,
et al. Emerging role of long noncoding RNAs in autoimmune diseases. Autoimmun Rev 2015;14:798–805.
15. Gibbons A, Udawela M, Dean B. Non-coding RNA as novel players in the pathophysiology of schizophrenia. Noncoding RNA 2018;4:E11.
17. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
18. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG,
et al. Non-small-cell lung cancer. Lancet 2011;378:1727–1740.
19. Alvarez M, Roman E, Santos ES, Raez LE. New targets for non-small-cell lung cancer therapy. Expert Rev Anticancer Ther 2007;7:1423–1437.
21. Yang Q, Yu Y, Sun Z, Pan Y. Long non-coding RNA PVT1 promotes cell proliferation and invasion through regulating miR-133a in ovarian cancer. Biomed Pharmacother 2018;106:61–67.
23. Wang M, Ma X, Zhu C, Guo L, Li Q, Liu M,
et al. The prognostic value of long non coding RNAs in non small cell lung cancer: a meta-analysis. Oncotarget 2016;7:81292–81304.
24. Guo D, Wang Y, Ren K, Han X. Knockdown of LncRNA PVT1 inhibits tumorigenesis in non-small-cell lung cancer by regulating miR-497 expression. Exp Cell Res 2018;362:172–179.
25. Chen W, Zhu H, Yin L, Wang T, Wu J, Xu J,
et al. lncRNA-PVT1 facilitates invasion through upregulation of MMP9 in non-small cell lung cancer cell. DNA Cell Biol 2017;36:787–793.
26. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M,
et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001;98:13784–13789.
27. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr,
et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2005;167:1763–1775.
28. Zhang Y, Xiang C, Wang Y, Duan Y, Liu C, Jin Y,
et al. lncRNA LINC00152 knockdown had effects to suppress biological activity of lung cancer via EGFR/PI3K/AKT pathway. Biomed Pharmacother 2017;94:644–651.
29. Zhou J, Zhi X, Wang L, Wang W, Li Z, Tang J,
et al. Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway. J Exp Clin Cancer Res 2015;34:135.
31. Mao C, Wu XY, Yang ZY, Threapleton DE, Yuan JQ, Yu YY,
et al. Concordant analysis of
KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep 2015;5:8065.
32. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D,
et al. Emergence of
KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532–536.
33. Tian T, Qiu R, Qiu X. SNHG1 promotes cell proliferation by acting as a sponge of miR-145 in colorectal cancer. Oncotarget 2018;9:2128–2139.
34. Sheng N, Tan G, You W, Chen H, Gong J, Chen D,
et al. MiR-145 inhibits human colorectal cancer cell migration and invasion via PAK4-dependent pathway. Cancer Med 2017;6:1331–1340.
35. Zhu Y, Li B, Liu Z, Jiang L, Wang G, Lv M,
et al. Up-regulation of lncRNA SNHG1 indicates poor prognosis and promotes cell proliferation and metastasis of colorectal cancer by activation of the Wnt/beta-catenin signaling pathway. Oncotarget 2017;8:111715–111727.
36. Wang H, Wang G, Gao Y, Zhao C, Li X, Zhang F,
et al. Lnc-SNHG1 activates the TGFBR2/SMAD3 and RAB11A/Wnt/beta-catenin pathway by sponging MiR-302/372/373/520 in invasive pituitary tumors. Cell Physiol Biochem 2018;48:1291–1303.
38. Luo Y, Ouyang J, Zhou D, Zhong S, Wen M, Ou W,
et al. Long noncoding RNA GAPLINC promotes cells migration and invasion in colorectal cancer cell by regulating miR-34a/c-MET signal pathway. Dig Dis Sci 2018;63:890–899.
39. Liu S, Mitra R, Zhao MM, Fan W, Eischen CM, Yin F,
et al. The potential roles of long noncoding RNAs (lncRNA) in glioblastoma development. Mol Cancer Ther 2016;15:2977–2986.
40. Ohba S, Hirose Y. Current and future drug treatments for glioblastomas. Curr Med Chem 2016;23:4309–4316.
43. Bastien JI, McNeill KA, Fine HA. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer 2015;121:502–516.
46. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S,
et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006;9:287–300.
47. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD,
et al. Functional network analysis reveals extended glioma-genesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005;65:8679–8689.
48. Ma Y, Zhou G, Li M, Hu D, Zhang L, Liu P,
et al. Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-kappaB signaling pathway. Neurochem Int 2018;118:233–241.
49. Li J, Zhou L. Overexpression of lncRNA DANCR positively affects progression of glioma via activating Wnt/beta-catenin signaling. Biomed Pharmacother 2018;102:602–607.
51. Feng T, Shao F, Wu Q, Zhang X, Xu D, Qian K,
et al. miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation. Oncotarget 2016;7:16205–16216.
52. Wang Y, Zhou Y, Yang Z, Chen B, Huang W, Liu Y,
et al. MiR-204/ZEB2 axis functions as key mediator for MALAT1-induced epithelial-mesenchymal transition in breast cancer. Tumour Biol 2017;39:1010428317690998.
53. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW,
et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557–563.
54. Zhao H, Langerod A, Ji Y, Nowels KW, Nesland JM, Tibshirani R,
et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 2004;15:2523–2536.
55. Deng X, Zhao Y, Wu X, Song G. Upregulation of CCAT2 promotes cell proliferation by repressing the P15 in breast cancer. Biomed Pharmacother 2017;91:1160–1166.
56. Wu ZJ, Li Y, Wu YZ, Wang Y, Nian WQ, Wang LL,
et al. Long non-coding RNA CCAT2 promotes the breast cancer growth and metastasis by regulating TGF-beta signaling pathway. Eur Rev Med Pharmacol Sci 2017;21:706–714.
57. Cai Y, He J, Zhang D. Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. Onco Targets Ther 2015;8:2657–2664.